home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 07/06/20

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - PSXP, KNDI, GNUS and SOLO among midday movers

Gainers:  Ayro (NASDAQ: AYRO )  +102% . More news on: Ayro, Inc., Electrameccanica Vehicles Corp., LM Funding America, Inc., Stocks on the move, , Read more ...

OBSV - ObsEva down 42% on late-stage linzagolix data

ObsEva SA ( OBSV -41.8% ) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzagolix in women with heavy menstrual bleeding due to uterine fibroids. More news on: ObsEva SA, AbbVie Inc., Myovant Sciences Ltd., ...

OBSV - ObsEva's linzagolix successful in late-stage uterine fibroid study

ObsEva SA (NASDAQ: OBSV ) announces positive results from a Phase 3 clinical trial, PRIMROSE 1 , evaluating Yselty (linzagolix) in women with heavy menstrual bleeding due to uterine fibroids. More news on: ObsEva SA, Healthcare stocks news, Stocks on the move, Read more ...

OBSV - ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

  PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24  PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52   Results confirm linzagolix as a p...
OBSV - ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

  Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESHRE Vir...

OBSV - ObsEva and Yuyuan Bio submits pre-IND dossier for nolasiban in China

ObsEva's (NASDAQ: OBSV ) partner Yuyuan BioScience Technology has submitted a pre-IND meeting request for nolasiban to the Center for Drug Evaluation at the Chinese National Medical Products Administration. More news on: ObsEva SA, Healthcare stocks news, Read more ...

OBSV - ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA

  Geneva, Switzerland and Boston, MA – July 1, 2020  - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reprod...
OBSV - ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids

Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release Phase ...

OBSV - ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020

Geneva, Switzerland and Boston, MA – June 9, 2020  - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive he...

OBSV - ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) , a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of...
Previous 10 Next 10